Close Menu
    Quds SunQuds Sun
    • Automotive
    • Business
    • Entertainment
    • Lifestyle
    • Luxury
    • News
    • Sports
    • Technology
    • Travel
    Quds SunQuds Sun
    Home » China’s first personalized neoantigen-targeted cancer vaccine receives NMPA’s clinical trial approval
    PR Newswire

    China’s first personalized neoantigen-targeted cancer vaccine receives NMPA’s clinical trial approval

    March 17, 2023
    Facebook WhatsApp Twitter Pinterest LinkedIn Telegram Tumblr Email Reddit VKontakte

    BEIJING, March 17, 2023 /PRNewswire/ — According the latest data released at the Clinical Trials Implied Approval section on the website of China’s Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA), Likang Life Sciences (hereinafter referred to as “Likang”) has received implied approval for the clinical trial of its personalized neoantigen-targeted vaccine for advanced solid tumors, LK101 Injection. This is the first personalized neoantigen vaccine & mRNA editing product approved by the NMPA to enter clinical stage.

    On December 22, 2022, Likang submitted an IND application for LK101 Injection to NMPA, and received application shortly after. LK101 Injection, the first in-house developed cancer vaccine candidates by Likang, is a personalized neoantigen-targeted cancer vaccine and also a dendritic cell (DC)-based mRNA vaccine that combines advantages of both mRNA technology and DC by transducing mRNA encoding personalized tumor antigen targets based on dozens of patient-specific tumor mutations information into dendritic cells.

    The mRNA editing technology is a highly convenient method that can encode multiple antigens at once while maintaining rapid, efficient expression, making it suitable for the development of personalized cancer treatments. DCs, which are highly specialized and strong antigen-presenting cells in human immune system, have been utilized in the development of tumor vaccines. DC vaccines have demonstrated high safety and good tolerance, effectively activating tumor-specific T cells and establishing immunological memory, resulting in long-term anti-cancer effects. The combination of mRNA vaccine and DC vaccine provides a potential breakthrough in the field of personalized neoantigen treatment, offering an effective and safe approach for patients to fight against cancer.

    In 2018, Likang collaborated with the Chinese PLA General Hospital to conduct an investigator-initiated clinical trial (IIT) of LK101 injection for postoperative liver cancer patients. The data showed that LK101 have good safety and tolerance, no grade I or higher drug-related adverse reactions reported. Activation of anti-tumor neoantigen immune response detected in all patients, showing significant advantages in terms of postoperative recurrence rate and survival rate.

    About Likang

    Likang Life Sciences is a leading Chinese innovative company dedicated to development of immune cell therapy, with tumor-specific neoantigen as the target, founded in 2017 by a team of local PhD. The company has established multiple platform, including the LNEATM platform, high-throughput antigen/TCR screening platform (HATSPTM), in vitro-transcribed (“IVT”)  mRNA technology platform, and large-scale automatic and totally closed cell drug production platform. Currently, Likang is fully deploying multiple pipelines with a focus on precision tumor immunotherapy, including tumor neoantigen analysis diagnostic, neoantigen tumor vaccines, and T-cell therapies based on a universal technical platform. Likang seeks to unlock the full potential of tumor neoantigens through its cutting-edge technologies.

    Cision View original content:https://www.prnewswire.co.uk/news-releases/chinas-first-personalized-neoantigen-targeted-cancer-vaccine-receives-nmpas-clinical-trial-approval-301774853.html

    Related Posts

    TÜV SÜD opens its International Technology & Innovation Campus in the Guangdong-Hong Kong-Macao Greater Bay Area

    November 20, 2026

    Huawei Unveils Financial AI Scaling Capabilities at Singapore FinTech Festival 2026

    November 20, 2026

    UnionPay International and Transsion Announce Global Partnership to Bring UnionPay Payments to T Wallet, Debuting in Pakistan

    November 19, 2026

    Lianlian DigiTech Launches LianLian XWorker, an AI Workforce Platform for Global Commerce

    November 19, 2026

    Getac Expands OS Choice for Highly Regulated Industries with Red Hat® Enterprise Linux® Certification Across Three Fully Rugged Devices

    November 19, 2026

    Sinopec Hosts Side Event at COP31’s CHINA PAVILION, Releases Energy and Green Fuel Outlooks

    November 19, 2026
    Latest News

    Air Arabia Egypt launches Cairo to Al Ain flights now

    November 20, 2026

    Regional budget carriers are aggressively capturing market share by deepening direct commercial connectivity across the Middle East. Highlighting this corporate expansion strategy, airline representatives confirm that Air Arabia Egypt launches Cairo to Al Ain flights starting December 2, 2026. The

    Botswana opens consultations on proposed 33 percent hike now

    November 19, 2026

    PM Modi meets Prince and Princess of Wales in New Delhi

    November 19, 2026

    Rand slips toward R17 as inflation and weak growth cloud outlook

    November 18, 2026

    DXB handles 50.4 million passengers in first nine months

    November 18, 2026

    Congo Ebola death toll reaches 5,568 as cases pass 11,000

    November 18, 2026

    Prabowo says DEFA can unlock $2 trillion ASEAN digital economy

    November 18, 2026

    Tunisia tourism revenues top $2.38 billion by end-October

    November 17, 2026
    © 2026 Quds Sun | All Rights Reserved
    • Home
    • Contact Us

    Type above and press Enter to search. Press Esc to cancel.